TubaEsfandyariMD
Gastroenterology • Kansas City, KSAdvanced Endoscopic Interventional
Assistant Professor, Internal Medicine, University Kansas School of Medicine
Dr. Esfandyari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3901 Rainbow Blvd
# Wescoe
Kansas City, KS 66160Phone+1 913-588-0455Fax+1 913-588-3975
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2003 - 2006
UMass Chan Medical SchoolResidency, Internal Medicine, 2001 - 2003
Tabriz University of Medical Sciences Class of 1994
Certifications & Licensure
MO State Medical License 2022 - 2026
KS State Medical License 2008 - 2025
MN State Medical License 2003 - 2009
OH State Medical License 2000 - 2002
American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Patient Understanding (Cognitive Debriefing) of a Daily Diary of Gastroparesis Symptoms Start of enrollment: 2011 Mar 01
Publications & Presentations
PubMed
- Safety of Same-Day Discharge After Gastric Peroral Endoscopic Myotomy in Patients with Refractory Gastroparesis: An International Multi-Center Study.Marita Salame, Yervant Ichkhanian, Nwal Hadaki, John M Wo, Sarah A Stainko
Gastrointestinal Endoscopy. 2025-02-19 - 10 citationsA randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis.Thomas L Abell, Braden Kuo, Tuba Esfandyari, Nathan D Pfeifer, Maria Grimaldi
Neurogastroenterology and Motility. 2023-04-01 - 14 citationsA Novel Oncolytic Herpes Capable of Cell-Specific Transcriptional Targeting of CD133± Cancer Cells Induces Significant Tumor Regression.Kaoru Terai, Danse Bi, Zhengian Liu, Kyle Kimura, Zohreh Sanaat
Stem Cells. 2018-08-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
